Firazyr (generic name: icatibant) is a medication specifically designed for the treatment of acute attacks of hereditary angioedema (HAE) in adults. Hereditary angioedema is a rare, genetic disorder characterized by sudden and severe swelling in various parts of the body, including the limbs, face, intestinal tract, and airways, which can be life-threatening if the swelling obstructs the airways. Firazyr works by blocking the action of bradykinin, a peptide that plays a key role in the development of swelling and inflammation associated with HAE attacks. By inhibiting bradykinin, Firazyr effectively reduces the swelling, pain, and severity of the attack. It is administered through a subcutaneous injection, allowing for rapid relief of symptoms.